EGFR, HER2 & Receptor Tyrosine Kinases

Cat. No.

AT1090

CAS No.

1801544-27-3

Losatuxizumab

Losatuxizumab is a monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR). It exhibits high affinity for various forms of EGFR, with EC50 values of 0.96 nM for wild-type EGFR, 0.09 nM for the EGFRC271A,C283A mutant, 0.12 nM for EGFRvIII, and 0.66 nM for EGFR1-501. This antibody is specifically designed for the study of cancers expressing EGFR, making it an essential tool for research in oncology and molecular biology.

Cat. No.

AT1113

CAS No.

2868265-50-1

Tilatamig

Tilatamig is a human monoclonal antibody of the IgG1 subtype that specifically targets both EGFR and MET receptors. This dual specificity enables it to interfere with key pathways involved in cellular proliferation and survival, making it a valuable tool for research in cancer biology where these receptors are implicated.

Cat. No.

AT1148

CAS No.

2171511-58-1

Amivantamab

Synonyms: JNJ-61186372

Amivantamab (JNJ-61186372) is a bispecific human antibody targeting EGFR and MET receptors, designed for its potent anticancer immune activity. This therapeutic antibody functions by inhibiting ligand binding, thereby promoting the endocytosis and subsequent degradation of receptor-antibody complexes. Furthermore, Amivantamab facilitates Fc-dependent cytokinesis in macrophages and enhances antibody-dependent cellular cytotoxicity in natural killer cells, making it a valuable tool in cancer immunotherapy research.

Cat. No.

AT1168

CAS No.

2367012-88-0

Anbenitamab

Synonyms: KN-026

Anbenitamab (KN-026) is a bispecific antibody engineered to target extracellular domains II and IV of human HER2, effectively blocking both ligand-dependent and ligand-independent signaling pathways associated with this receptor. The inclusion of the IgG1 Fc fragment enhances its interaction with FcRγIIIa, facilitating robust antibody-dependent cell-mediated cytotoxicity (ADCC) and effectively inhibiting tumor cell proliferation. This antibody is primarily researched for its therapeutic potential in HER2-positive metastatic breast cancer (MBC).

Cat. No.

AT1202

CAS No.

1188275-92-4

Narnatumab

Synonyms: IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab

Narnatumab (IMC-RON8) is a human monoclonal antibody designed to neutralize RON receptor activity by inhibiting its interaction with the macrophage-stimulating protein (MSP). This antibody demonstrates a high affinity for the RON receptor with a dissociation constant (Kd) of 32 pM. Narnatumab is primarily utilized in cancer research, where it serves as a critical tool for studying the role of the RON receptor in tumor progression and metastasis.

Cat. No.

AT1243

CAS No.

959963-46-3

Imgatuzumab

Synonyms: RG 7160; RO 5083945; Anti-EGFR Recombinant Antibody

Imgatuzumab (RG 7160) is a humanized monoclonal antibody specifically targeting the Epidermal Growth Factor Receptor (EGFR). It functions primarily as an immunomodulator. This antibody is utilized in the study of various cancers, providing a valuable tool for researchers exploring the role of EGFR in oncogenic processes and therapeutic interventions.

Cat. No.

AT1251

CAS No.

2169946-15-8

Zanidatamab

Synonyms: ZW 25

Zanidatamab (ZW25) is a humanized, bispecific monoclonal antibody designed to target two distinct epitopes (ECD2 and ECD4) of the human epidermal growth factor receptor 2 (HER2). This antibody exhibits potent anti-tumor activity by engaging these specific regions, enhancing its therapeutic efficacy in oncology research. Zanidatamab is primarily used in studies investigating the treatment of HER2-positive cancers.

Cat. No.

AT1260

CAS No.

2140172-41-2

Serclutamab

Synonyms: PR-1594407; DC-1630423

Serclutamab is a humanized chimeric monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), subclass IgG1-κ. It is produced in Chinese Hamster Ovary (CHO) cells, ensuring high fidelity and stability in its structure. This antibody is designed for use in research studies focused on the biological pathways influenced by EGFR, including cellular proliferation, differentiation, and survival.

Cat. No.

AT1263

CAS No.

2251771-76-1

Pimurutamab

Pimurutamab is a humanized IgG1-κ monoclonal antibody specifically designed to target the Epidermal Growth Factor Receptor (EGFR). This antibody is produced in CHO-K1 cells, ensuring high fidelity and consistency in performance. Pimurutamab binds to EGFR with high specificity, making it an invaluable tool for research focused on cancer biology and therapeutic development where EGFR plays a critical role.

Cat. No.

AT1267

CAS No.

1448327-63-6

Lumretuzumab

Synonyms: Anti-Human ERBB3 Recombinant Antibody

Lumretuzumab is a humanized monoclonal antibody that targets the human epidermal growth factor receptor 3 (HER3 or ERBB3). This recombinant antibody is designed for use in cancer research, facilitating the study of HER3's role in oncogenic signaling pathways and tumor progression. Lumretuzumab's specificity for HER3 makes it a valuable tool for investigating potential therapeutic interventions in HER3-associated malignancies.

Cat. No.

AT1281

CAS No.

2771389-44-5

Opelkibart

Opelkibart is a human IgG1 κ monoclonal antibody targeting the KIT receptor. For control experiments, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT1285

ELB-031

Anti-TYRO3 (ELB031) is a monoclonal antibody specifically designed to target and bind to the TYRO3 and MERTK receptors. This antibody is produced for the purpose of studying the signaling pathways and biological functions associated with these receptor tyrosine kinases, which are implicated in various cellular processes including cell survival, migration, and differentiation. Anti-TYRO3 (ELB031) is ideal for use in research applications focused on cancer, immune regulation, and neurological diseases where TYRO3 and MERTK play critical roles.

Cat. No.

AT1288

CAS No.

2648260-93-7

Becotatug

Synonyms: JMT-101

Becotatug (JMT-101) is an IgG1 monoclonal antibody specifically designed to target the Epidermal Growth Factor Receptor (EGFR). This antibody can be conjugated with Afatinib and Osimertinib, enabling its use as a synthetic antibody-drug conjugate (ADC) for targeted cancer therapy. This feature allows for the precise delivery of therapeutic agents to EGFR-expressing cells, potentially enhancing treatment efficacy and reducing off-target effects.

Cat. No.

AT1293

CAS No.

1310460-86-6

Modotuximab

Synonyms: DS 1024

Modotuximab (DS 1024) is a chimeric monoclonal antibody of the IgG1κ isotype, designed to specifically target the human Epidermal Growth Factor Receptor (EGFR). This antibody recognizes non-overlapping epitopes located on domain III of the EGFR protein, a region preserved in the EGFR variant III (EGFRvIII). Modotuximab demonstrates potent antitumor activity in vivo, making it a valuable tool for research in cancer biology and therapeutic development.

Cat. No.

AT1308

CAS No.

1912423-61-0

Enapotamab

Synonyms: Anti-AXL/UFO Reference Antibody (enapotamab

Enapotamab is a reference antibody targeting AXL/UFO, which is instrumental in synthesizing Bcl-xl inhibitor antibody-drug conjugates. This antibody serves as a critical tool in the development of targeted therapies, facilitating research into novel cancer treatment modalities.

Cat. No.

AT1318

Bemarituzumab (FUT8-KO)

Bemarituzumab (FUT8-KO) is a monoclonal antibody targeting FGFR2b, expressed in CHO cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). This genetic modification leads to the absence of core fucose in the polysaccharide structure of the Fc domain, significantly enhancing the antibody's antibody-dependent cellular cytotoxicity (ADCC). The lack of fucose results in increased affinity for human FcγRIIIa, potentially improving therapeutic efficacy. Bemarituzumab (FUT8-KO) is designed for advanced research applications focusing on cancer therapy and the study of FGFR2b-related biological pathways.

Cat. No.

AT1365

Anti-c-Kit/CD117 Antibody (SR-1)

The Anti-c-Kit/CD117 Antibody (SR-1) is a chimeric mouse monoclonal antibody of the IgG2a, κ subclass, designed to specifically target human c-Kit/CD117. This antibody is ideal for research focused on the biology and pathology of c-Kit/CD117-expressing cells. For accurate experimental control, it is recommended to use Mouse IgG2a kappa Isotype Control in conjunction with this antibody to ensure specificity and consistency in results.

Cat. No.

AT1367

SAIT-301

SAIT-301 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the hepatocyte growth factor receptor (HGFR), also known as c-Met. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cat. No.

AT1378

CAS No.

2489584-93-0

Fepixnebart

Fepixnebart is a humanized IgG4κ monoclonal antibody that specifically targets transforming growth factor-alpha (TGFA). This antibody is engineered for stability and minimal immune system engagement, making it an ideal tool for research into TGF-alpha's role in cell proliferation, differentiation, and its implications in oncological disorders.

Cat. No.

AT1382

CAS No.

380610-27-5

Pertuzumab

Pertuzumab is a humanized IgG1 monoclonal antibody designed to inhibit HER2 dimerization. This targeted mechanism of action makes it particularly effective in the treatment of metastatic HER2-positive breast cancer. Pertuzumab binds specifically to the HER2 receptor, blocking its ability to form dimers and activate downstream signaling pathways that promote tumor growth and survival. This agent is utilized primarily in research focused on understanding and treating HER2-positive breast cancer.

Cat. No.

AT1401

CAS No.

872514-65-3

Rilotumumab

Synonyms: AMG 102

Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor (HGF), designed to inhibit HGF/MET signaling pathways. This antibody demonstrates potent anti-tumor activity and is primarily utilized in the study of castration-resistant prostate cancer (CRPC) and other solid tumors. Rilotumumab offers a strategic tool for researchers investigating the role of HGF/MET interactions in cancer progression and therapeutic resistance.

Cat. No.

AT1403

Panitumumab (anti-EGFR)

Panitumumab is a fully human monoclonal antibody of the IgG2 subclass, designed to specifically target the epidermal growth factor receptor (EGFR). It exhibits potent anti-tumor properties by inhibiting tumor cell proliferation, survival, and angiogenesis. This monoclonal antibody is particularly useful in cancer research, including studies focused on colon cancer, providing a critical tool for understanding the role of EGFR in cancer pathology and therapy.

Cat. No.

AT1414

CAS No.

2930815-95-3

Caxmotabart

Caxmotabart is a humanized IgG1κ monoclonal antibody designed to specifically target ERBB2. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Cat. No.

AT1420

CAS No.

1646321-00-7

Tomuzotuximab

Synonyms: Anti-Human EGFR Recombinant Antibody

Tomuzotuximab is a fully human, glycoengineered IgG1 monoclonal antibody specifically targeting the Epidermal Growth Factor Receptor (EGFR). This recombinant antibody is engineered to bind selectively to EGFR, a receptor critically involved in the proliferation and survival of various cancer cells. By inhibiting EGFR signaling, Tomuzotuximab exhibits potent anticancer activities, making it a valuable tool for research in oncology and therapeutic development.

Cat. No.

AT1451

Anti-IGF1R/CD221 Antibody